Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program
Vanda Pharmaceuticals Inc VNDA
News
Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting
Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder
Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences
Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission
NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.
Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results
Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026
Vanda Pharmaceuticals Gain Following FDA Approval of Bipolar, Schizophrenia Treatment
Vanda Pharmaceuticals Gets FDA Approval for Bipolar, Schizophrenia Treatment
Vanda Shares Fall Premarket as FDA Again Rejects Hetlioz for Jet Lag
Vanda Pharma Shares Rise After FDA Approves Motion Sickness Treatment
Vanda Pharmaceuticals Rises on FDA Biologics License Application
FDA Lifts Hold on Vanda Pharmaceuticals' Motion Sickness Drug
Vanda Pharmaceuticals Drugs to Get More FDA Reviews to Resolve Legal Disputes
United States